Trial Profile

A phase III study of Cannabidiol in prevention of acute graft versus host disease (GVHD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Sep 2019 According to an Kalytera Therapeutics media release, the company announced that it is updating the terms of its private placement previously announced on August 21, 2019. The Company proposes to raise up to approximately CDN $1.5 million (USD $1.14 million) pursuant to the Private Placement.
21 Aug 2019 According to a Kalytera Therapeutics media release, the company intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement. The proceeds will be utilized to fund preparatory work for initiation of phase 3 study in prevention of acute graft versus host disease.
05 Oct 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com